Glenmede Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.48M | Buy |
7,819
+146
| +2% | +$25.5K | 0.01% | 635 |
|
|
2025
Q4 | $1.3M | Buy |
+7,673
| New | +$1.18M | 0.01% | 655 |
|
|
2021
Q4 | – | Sell |
-2,714
| Closed | -$352K | – | 1351 |
|
|
2021
Q3 | $352K | Sell |
2,714
-32,763
| -92% | -$4.95M | ﹤0.01% | 986 |
|
|
2021
Q2 | $6.3M | Buy |
35,477
+2,492
| +8% | +$432K | 0.03% | 383 |
|
|
2021
Q1 | $5.42M | Sell |
32,985
-7,215
| -18% | -$1.19M | 0.03% | 386 |
|
|
2020
Q4 | $6.63M | Buy |
40,200
+5,034
| +14% | +$750K | 0.04% | 368 |
|
|
2020
Q3 | $5.01M | Buy |
35,166
+737
| +2% | +$91.4K | 0.03% | 390 |
|
|
2020
Q2 | $3.8M | Sell |
34,429
-90,279
| -72% | -$9.98M | 0.02% | 403 |
|
|
2020
Q1 | $18.6M | Hold |
124,708
| – | – | 0.08% | 287 |
|
|
2019
Q4 | $18.6M | Buy |
124,708
+101,015
| +426% | +$13.7M | 0.08% | 287 |
|
|
2019
Q3 | $3.04K | Buy |
23,693
+273
| +1% | +$36.6K | 0.01% | 553 |
|
|
2019
Q2 | $3.34K | Buy |
23,420
+511
| +2% | +$68.7K | 0.01% | 552 |
|
|
2019
Q1 | $3.27K | Buy |
22,909
+19,218
| +521% | +$2.51M | 0.01% | 553 |
|
|
2018
Q4 | $457 | Buy |
3,691
+3,652
| +9,364% | +$542K | ﹤0.01% | 877 |
|
|
2018
Q3 | $6K | Buy |
+39
| New | +$6.71K | ﹤0.01% | 1396 |
|
|
2017
Q4 | – | Sell |
-13
| Closed | -$1K | – | 2730 |
|
|
2017
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 2653 |
|
|
2017
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 2588 |
|
|
2017
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 2588 |
|
|
2016
Q4 | $1K | Hold |
13
| – | – | ﹤0.01% | 2410 |
|
|
2016
Q3 | $1K | Sell |
13
-3,139
| -100% | -$423K | ﹤0.01% | 2479 |
|
|
2016
Q2 | $444K | Sell |
3,152
-3,378
| -52% | -$498K | ﹤0.01% | 959 |
|
|
2016
Q1 | $852K | Sell |
6,530
-93,535
| -93% | -$11.6M | 0.01% | 778 |
|
|
2015
Q4 | $14.1M | Buy |
100,065
+27,561
| +38% | +$3.82M | 0.1% | 301 |
|
|
2015
Q3 | $9.63M | Buy |
72,504
+72,494
| +724,940% | +$12.5M | 0.07% | 342 |
|
|
2015
Q2 | $1K | Sell |
10
-690
| -99% | -$124K | ﹤0.01% | 2543 |
|
|
2015
Q1 | $120K | Sell |
700
-8
| -1% | -$1.37K | ﹤0.01% | 1422 |
|
|
2014
Q4 | $115K | Sell |
708
-42
| -6% | -$6.97K | ﹤0.01% | 1478 |
|
|
2014
Q3 | $120K | Sell |
750
-150
| -17% | -$23.1K | ﹤0.01% | 1382 |
|
|
2014
Q2 | $132K | Hold |
900
| – | – | ﹤0.01% | 1311 |
|
|
2014
Q1 | $124K | Hold |
900
| – | – | ﹤0.01% | 1343 |
|
|
2013
Q4 | $113K | Hold |
900
| – | – | ﹤0.01% | 1362 |
|
|
2013
Q3 | $82K | Buy |
+900
| New | +$72.6K | ﹤0.01% | 1452 |
|
Other funds holding JAZZ
VPM
VCM
EC
Glenmede Trust's JAZZ Position: Q1 2026 in Review
Glenmede Trust increased its Jazz Pharmaceuticals (JAZZ) stake by 1.9% in Q1 2026, buying an estimated $25.5K and bringing the position to 7,819 shares worth $1.48M. The position accounts for 0.01% of the portfolio, ranked #635.
Glenmede Trust first reported a position in JAZZ in Q3 2013 and has held it in 32 quarters since. The position peaked at $18.6M in Q1 2020. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Glenmede Trust held 7,819 shares of Jazz Pharmaceuticals worth $1.48M as of Q1 2026.
- Glenmede Trust bought 146 Jazz Pharmaceuticals shares in Q1 2026, an estimated $25.5K.
- Jazz Pharmaceuticals made up 0.01% of Glenmede Trust's portfolio in Q1 2026, its #635 holding.
- Glenmede Trust first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 32 quarters since.
- Glenmede Trust's Jazz Pharmaceuticals position peaked at $18.6M in Q1 2020.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.